logo-loader
Aston Martin Lagonda Global Holdings PLC

Aston Martin shares drive higher as raft of brokers initiate coverage two months after flotation

US investment banks Goldman Sachs and BofA Merrill Lynch both started Aston Martin with ‘buy’ ratings, while Swiss bank Credit Suisse tagged it as an ‘outperform'

Aston Martin car
But global banking giant HSBC and French broker Kepler Chevreux both started the stock with ‘hold’ ratings

Shares in Aston Martin Lagonda Global Holdings PLC (LON:AML) drove higher on Tuesday as a raft of brokers initiated coverage on the luxury carmaker two months after its London Stock Exchange flotation.

US investment banks Goldman Sachs and BofA Merrill Lynch both started the stock with ‘buy’ ratings, while Credit Suisse tagged it as an ‘outperform’.

READ: Aston Martin moves slowly into gear in conditional trading

In a note to clients, the Swiss bank’s analysts forecast Aston Martin reporting a 22% compound annual growth rate (CAGR) in unit sales by 2022, making it the world's fastest-growing automotive brand.

They think the key catalyst will be the start of production for the Aston Martin DBX sports utility vehicle (SUV) by the end of 2019.

The analysts also believe the car group’s Second Century Plan will enable it to grow its top-line and margins significantly.

Less optimistic, however, were global banking giant HSBC and blue-chip French broker Kepler Chevreux, both of whom started Aston Martin shares with ‘hold’ ratings.

In early afternoon trading, Aston Martin shares were nearly 1% higher at 1,610p, although they still remained well below the 1,900p offer price following a poor opening few months trading.

Quick facts: Aston Martin Lagonda Global Holdings PLC

Price: £4.59

Market: LSE
Market Cap: £1.05 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Scancell back in the clinic with a phase II trial of its...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway tells Proactive London's Andrew Scott they've begun the UK arm of the phase II trial of its flagship skin cancer treatment. The trial is testing the safety and efficacy of SCIB1 in metastatic melanoma patients who are also receiving Merck’s...

7 hours, 47 minutes ago

2 min read